Cargando…
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution o...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406852/ https://www.ncbi.nlm.nih.gov/pubmed/37550377 http://dx.doi.org/10.1038/s41598-023-39681-7 |
_version_ | 1785085828164222976 |
---|---|
author | Li, Dateng Xu, Meng Hooper, Andrea T. Rofail, Diana Mohammadi, Kusha A. Chen, Yiziying Ali, Shazia Norton, Thomas Weinreich, David M. Musser, Bret J. Hamilton, Jennifer D. Geba, Gregory P. |
author_facet | Li, Dateng Xu, Meng Hooper, Andrea T. Rofail, Diana Mohammadi, Kusha A. Chen, Yiziying Ali, Shazia Norton, Thomas Weinreich, David M. Musser, Bret J. Hamilton, Jennifer D. Geba, Gregory P. |
author_sort | Li, Dateng |
collection | PubMed |
description | Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution of individual symptoms was assessed for resolution patterns across risk factors, and baseline SARS-CoV-2-specific antibody responses against S1 and N domains. CAS + IMD versus placebo provided statistically significant resolution for 17/23 symptoms, with greater response linked to absence of endogenous anti–SARS-CoV-2 immunoglobulin (Ig)G, IgA, or specific neutralizing antibodies at baseline, or high baseline viral load. Resolution of five key symptoms (onset days 3–5)—dyspnea, cough, feeling feverish, fatigue, and loss of appetite—independently correlated with reduced hospitalization and death (hazard ratio range: 0.31–0.56; P < 0.001–0.043), and was more rapid in CAS + IMD-treated patients lacking robust early antibody responses. Those who seroconverted late still benefited from treatment. Thus, highly neutralizing COVID-19-specific antibodies provided by CAS + IMD treatment accelerated key symptom resolution associated with hospitalization and death in those at high risk for severe disease as well as in those lacking early, endogenous neutralizing antibody responses. |
format | Online Article Text |
id | pubmed-10406852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-104068522023-08-09 Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles Li, Dateng Xu, Meng Hooper, Andrea T. Rofail, Diana Mohammadi, Kusha A. Chen, Yiziying Ali, Shazia Norton, Thomas Weinreich, David M. Musser, Bret J. Hamilton, Jennifer D. Geba, Gregory P. Sci Rep Article Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution of individual symptoms was assessed for resolution patterns across risk factors, and baseline SARS-CoV-2-specific antibody responses against S1 and N domains. CAS + IMD versus placebo provided statistically significant resolution for 17/23 symptoms, with greater response linked to absence of endogenous anti–SARS-CoV-2 immunoglobulin (Ig)G, IgA, or specific neutralizing antibodies at baseline, or high baseline viral load. Resolution of five key symptoms (onset days 3–5)—dyspnea, cough, feeling feverish, fatigue, and loss of appetite—independently correlated with reduced hospitalization and death (hazard ratio range: 0.31–0.56; P < 0.001–0.043), and was more rapid in CAS + IMD-treated patients lacking robust early antibody responses. Those who seroconverted late still benefited from treatment. Thus, highly neutralizing COVID-19-specific antibodies provided by CAS + IMD treatment accelerated key symptom resolution associated with hospitalization and death in those at high risk for severe disease as well as in those lacking early, endogenous neutralizing antibody responses. Nature Publishing Group UK 2023-08-07 /pmc/articles/PMC10406852/ /pubmed/37550377 http://dx.doi.org/10.1038/s41598-023-39681-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Li, Dateng Xu, Meng Hooper, Andrea T. Rofail, Diana Mohammadi, Kusha A. Chen, Yiziying Ali, Shazia Norton, Thomas Weinreich, David M. Musser, Bret J. Hamilton, Jennifer D. Geba, Gregory P. Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles |
title | Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles |
title_full | Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles |
title_fullStr | Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles |
title_full_unstemmed | Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles |
title_short | Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles |
title_sort | casirivimab + imdevimab accelerates symptom resolution linked to improved covid-19 outcomes across susceptible antibody and risk profiles |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406852/ https://www.ncbi.nlm.nih.gov/pubmed/37550377 http://dx.doi.org/10.1038/s41598-023-39681-7 |
work_keys_str_mv | AT lidateng casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT xumeng casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT hooperandreat casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT rofaildiana casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT mohammadikushaa casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT chenyiziying casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT alishazia casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT nortonthomas casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT weinreichdavidm casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT musserbretj casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT hamiltonjenniferd casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles AT gebagregoryp casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles |